{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-095508","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.727333+00:00","generated_at":"2026-06-03T22:57:25.992387+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Mereo BioPharma extends cooperation with Rubric Capital; Justin Roberts to remain on board through 2025 AGM","bullets":["Extension letter dated April 15, 2024 waives resignation requirement for director Justin Roberts after 2024 AGM.","Termination date of Cooperation Agreement extended to immediately after the 2025 annual shareholder meeting.","Cooperation Agreement originally dated October 28, 2022 between Mereo and Rubric Capital Management L.P."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-095508","json":"https://secwatch.observer/filing/0001193125-24-095508.json","markdown":"https://secwatch.observer/filing/0001193125-24-095508.md","text":"https://secwatch.observer/filing/0001193125-24-095508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524095508/0001193125-24-095508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524095508/d818381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:57:25.992387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99b1438a81f064baae7d3434563ad3919796b88e","claim":"Mereo BioPharma Group plc entered into Extension Letter to Cooperation Agreement with Rubric Capital Management L.P. valued at Extension Letter waiving resignation requirement and extending termination date to after 2025 annual (effective 2024-04-15).","evidence_excerpt":"On April 15, 2024, Mereo BioPharma Group plc (the “Company”) entered into an extension letter, effective as of April 15, 2024 (the “Extension Letter”) to the cooperation agreement, dated October 28, 2022 (the “Cooperation Agreement”), between the Company and Rubric Capital Management L.P. (“Rubric Capital”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524095508/0001193125-24-095508-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Rubric Capital Management L.P."},{"label":"Value","value":"Extension Letter waiving resignation requirement and extending termination date to after 2025 annual"},{"label":"Effective","value":"2024-04-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}